Award: CAMPAIGN AWARDS \ C05. Healthcare: Ethical

Janssen has been involved in cancer research for many decades and today the company is recognized as a leader in oncology medical innovation, having introduced several medicines in recent years to treat solid tumors and more recently hematological malignancies, also known as blood cancers.

In Australia, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) and Mantle Cell Lymphoma (MCL) are blood cancers with a low incidence, but with high rates of recurrence.

Until now treatment options for these patients have been limited, meaning the launch and reimbursement of a new first-in-class medicine that has been shown in clinical research to delay progression of the illness, was a critical milestone for patients.

A Pharmaceutical Benefits Scheme (PBS) launch is a critical opportunity to communicate the value our products provide to patients, clinicians and the community more broadly and the team were delighted to be approached to work with the Australian Federal Government on a media announcement to ensure widespread awareness of this milestone.